Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C. Yatim N, et al. Among authors: aractingi s. Sci Adv. 2021 Aug 18;7(34):eabg4081. doi: 10.1126/sciadv.abg4081. Print 2021 Aug. Sci Adv. 2021. PMID: 34407944 Free PMC article.
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: aractingi s. Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Invest New Drugs. 2017. PMID: 28396974
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: aractingi s. Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31. Invest New Drugs. 2017. PMID: 28569347
Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C, Hoffmann C, Kramkimel N, Plée J, Franck N, Vanhaecke C, Goldman-Lévy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F, Guégan S. Lheure C, et al. Among authors: aractingi s. Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028. Acta Derm Venereol. 2019. PMID: 30176045 Free article. No abstract available.
Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study.
Bettuzzi T, Deroux A, Jachiet M, Farhat MM, Wipff J, Fabre M, Bouillet L, Kramkimel N, Aractingi S, Dupin N, Terrier B. Bettuzzi T, et al. Among authors: aractingi s. Ann Rheum Dis. 2019 Oct;78(10):1446-1448. doi: 10.1136/annrheumdis-2019-215605. Epub 2019 Jun 12. Ann Rheum Dis. 2019. PMID: 31189550 No abstract available.
347 results